Introduction
============

Given the prevalence of pregnant women who use drugs that block neurotransmitter reuptake, such as antidepressants, anti-anxiety medications, or antipsychotics as well as illegal drugs of abuse (Ritz et al., [@B79]; Kessler et al., [@B54]; Cooper et al., [@B19]; Thomas and Palmiter, [@B95]), it is surprising to find so little data on the effects of alterations in various neurotransmitter systems on maternal behavior (MB). Depression is among the most prevalent acute and chronic mental health conditions reported by perinatal women (Gaynes et al., [@B29]) and has been estimated to occur in 8--20% of women of childbearing age (Weissman et al., [@B98]; Kessler et al., [@B53]; Ferro et al., [@B28]). One study in 2003 estimated that approximately 13% of women take an antidepressant at some point during their pregnancy (Cooper et al., [@B20]). Many antidepressants commonly prescribed during pregnancy (Goldberg and Nissim, [@B31]) differentially act as reuptake inhibitors of norepinephrine (NE), dopamine (DA), and/or serotonin (5-HT) systems (Marek et al., [@B63]; Porrino et al., [@B78]; Kessler et al., [@B53]; Schatzberg, [@B86]; Bennett et al., [@B6]; Grover et al., [@B34]). Therefore, manipulation of neurotransmitter systems in a preclinical model of MB is a potentially useful pharmacological tool to explore their relative contribution to this behavior.

Preclinical models using neurotransmitter reuptake inhibitors during various stages of pregnancy have reported disruptions in MB (Gore, [@B32]; Johns et al., [@B40], [@B41]; Lerch-Haner et al., [@B57]; Cummings et al., [@B21]; Strathearn and Mayes, [@B93]) postpartum maternal aggression (MA; Johns et al., [@B48]; Lonstein and Gammie, [@B61]) and changes in oxytocin, a neuropeptide known to play an important role in both human and rodent pregnancy, parturition, and subsequent MB (Johns et al., [@B44], [@B43]; Bosch et al., [@B9]; Feldman et al., [@B26]; Levine et al., [@B58]; Neumann, [@B70]). To date, there is sparse information on the effects of reuptake inhibition of NE or combined NE and 5-HT systems during pregnancy on subsequent measures of MB. In general, central NE depletion and changes in NE metabolism have been associated with disruptions in the onset of MB in rats (Rosenberg et al., [@B80]; Thomas and Palmiter, [@B95]). Additionally, studies have found that mice lacking NE show impaired MB and that this impairment can be reversed if NE is restored before parturition (Thomas and Palmiter, [@B95]).

The 5-HT system has been associated with specific components of MB in animal models, including promotion of lactation, breastfeeding, and oxytocin secretion (Saydoff et al., [@B85]; Bagdy et al., [@B2]; Bagdy and Kalogeras, [@B1]; Uvnas-Moberg et al., [@B97]; Nissen et al., [@B73]), whereas reduced 5-HT levels are generally associated with increased aggression (Miczek et al., [@B68]). Keer and Stern ([@B51]) found that following an intracerebral ventricular infusion of a 5-HT antagonist, crouching behavior in rat dams on postpartum day (PPD) 6 was not disturbed, but when injected into the nucleus accumbens, crouching duration was increased. Johns et al. ([@B41]) reported that gestational treatment with the 5-HT reuptake inhibitor fluoxetine resulted in strong trends for decreased crouching in dams treated with the high dose compared to controls, and that all doses of fluoxetine treatment increased levels of licking and touching of pups. These same dams also had an increased level of MA toward an intruder on PPD 6, indicating a probable role for 5-HT in pup-directed MB and MA (Johns et al., [@B41]).

A single study has investigated the effects of 5-HT reuptake inhibition given during the postpartum period on human maternal--infant interactions. It found that in depressed women, SSRIs can increase maternal gratification (the mother's appreciation of motherhood), but did not improve maternal--infant interactions at 8 weeks postpartum (Logsdon et al., [@B60]). Although fluoxetine's effect on child abuse in humans has not been examined directly, it has been found to decrease general levels of impulsive aggressive behaviors (Coccaro and Kavoussi, [@B15]; Coccaro et al., [@B16]). Yet interestingly, the tricyclic antidepressant amitriptyline, which acts in part by inhibiting 5-HT and NE but not DA reuptake, has been found to increase levels of aggression (Soloff et al., [@B90], [@B91]). While these studies were conducted in non-lactational adults with psychiatric conditions, they suggest that the combined reuptake of 5-HT and NE might interact to differentially alter aggression than either 5-HT or NE alone. While NE has been previously associated with increased aggression in humans (Chichinadze et al., [@B14]) and parallel findings of NE and aggression in animal models have been shown in male rodents (Matsumoto et al., [@B65]) it is important to note that the few studies that have examined NE-induced alterations in females have shown little association between aggression and NE (Scholtens et al., [@B87]; Sorensen et al., [@B92]). This suggests that NE involvement in aggressive behavior is sex specific. There are no published reports, to our knowledge, on NE's role in postpartum aggression. Therefore, combined 5-HT/NE reuptake inhibition could behaviorally manifest itself similarly to what we previously observed following 5-HT alone. With regard to MB, studies suggest NE plays a role in the onset of MB (Rosenberg et al., [@B80]), while 5-HT-induced changes have been associated more often with active pup-induced MBs, i.e., licking, touching, and crouching over pups (Johns et al., [@B41]). Therefore, combined reuptake inhibition could result in greater disruptions in MB than either alone. However, there are a very limited number of studies that explore behavioral consequences from drug exposure during pregnancy on subsequent MB. It is currently unknown whether reuptake inhibition of the combined 5-HT and NE systems compared to either system individually might differentially alter MB or MA.

Increased oxytocin levels in several brain regions \[medial preoptic area (MPOA), ventral tegmental area (VTA), hippocampus, and amygdala\] at critical time points during pregnancy or in the postpartum period have been shown to be extremely important in rodent MB and may also play a role in MA. Alterations in the oxytocin system (peptide levels, receptors, and peptide synthesis) in these regions are correlated with abnormalities in MB and/or MA (Ferris et al., [@B27]; Bosch et al., [@B9]; Febo et al., [@B25]; Neumann, [@B71]). Of interest to the work presented here, studies suggest that decreased oxytocin levels in the amygdala (Lubin et al., [@B62]) and the MPOA and VTA (Pedersen et al., [@B76]; Elliott et al., [@B24]; Johns et al., [@B43]) are associated with increased postpartum aggression and deficits in maternal care, respectively. 5-HT receptors have been shown to regulate oxytocin neurons (Sawchenko et al., [@B84]) and stimulate oxytocin release (Jorgensen et al., [@B49]), and administration of 5-HT antagonists blocks stress-induced increases in oxytocin secretion (Jorgensen et al., [@B50]). NE is also an important contributor to the release of oxytocin, speculated to be even more important than 5-HT (Russell et al., [@B81]; Lipschitz et al., [@B59]), and NE reuptake inhibitors have been shown to increase hypothalamic oxytocin potency (Bealer and Flynn, [@B3]). Oxytocin is reduced following gestational treatment with fluoxetine, amfonelic acid, and the combination of both drugs (Johns et al., [@B41]). It is unknown if reuptake inhibition of NE, or of both NE and 5-HT, will alter oxytocin at critical periods in the early postpartum period, which could, if true, impact the early maternal environment.

The present study seeks to extend previous findings to determine the effects of gestational treatment with the neurotransmitter reuptake inhibitors amitriptyline (combined 5-HT and NE systems) and desipramine (NE system) on MB using a previously established preclinical model (Johns et al., [@B41]). We hypothesized that gestational treatment with amitriptyline and to a lesser degree desipramine alone would decrease MB resulting from the additive effect of combined neurotransmitter reuptake. Additionally, combined reuptake inhibition was expected to increase MA relative to desipramine treatment alone. Associated increases in aggression were predicted to correlate with decreased oxytocin levels in the amygdala following aggression testing as oxytocin levels have been shown to be inversely correlated with higher aggression levels in this region in previous studies (Lubin et al., [@B62]). Alternatively, a previous study using combined serotonin and dopamine reuptake inhibitors during gestation resulted in lower levels of oxytocin in the hippocampus associated with somewhat increased levels of MA on PPD 6, which implicates this region as one of interest as well (Johns et al., [@B41]). Given previous peptide level findings, this study also examined oxytocin levels as opposed to receptors as an initial level of comparison between groups.

Materials and Methods
=====================

Subjects
--------

Virgin female Sprague-Dawley rats (200--230 g) were group-housed in a temperature and humidity controlled room for a 7-day habituation period prior to breeding. Females were then individually housed with a sexually active male until conception was noted by the presence of a sperm plug. On the day a sperm plug was discovered, designated as gestation day (GD) 0, the female was removed from the breeding cage, randomly assigned to a treatment group (see below), individually housed, and provided food (Purina Rat Chow) and water *ad libitum*. Pregnant females were maintained on a reversed 12:12 hour light cycle (lights out at 0900) for 8 days, then transferred to a room with a regular 12:12 hour light cycle (lights on at 0700) for the remainder of the experiment, a procedure that generally results in dams delivering their litters during daylight hours (Mayer and Rosenblatt, [@B66]).

Choice of drugs
---------------

The drugs, amitriptyline and desipramine, were chosen specifically for these studies based on our goals and the attributes of the drugs at the highest doses utilized in this study and following consultation with our pharmacology consultant (Dr. Brian McMillen). With minimal literature available to facilitate even high dose selection (see remainder of this paragraph for review), medium and low doses were chosen relative to high dose for a descending dose response curve. Amitriptyline is a tertiary amine with preference for both the 5-HT and NE transporters, with a half-life in the rat of around 8--12 h. Review of available literature suggests that doses of 10 mg/kg or less of amitriptyline ensure moderate inhibition of both the 5-HT and NE transporters (Henderson and McMillen, [@B37]). Amitriptyline's inhibition of both 5-HT and NE transporters are considered comparable in this experimental paradigm because amitriptyline has a similar binding affinity for 5-HT and NE transporters in the adult rat (see Ki column of Table [1](#T1){ref-type="table"}), particularly at the likely cerebral spinal fluid concentrations achieved following amitriptyline doses utilized in this study (see CSF column of Table [1](#T1){ref-type="table"}). Desipramine, a secondary amine with the greatest known selectivity for the NE transporter, has a half-life of about 8 h in the rat. Desipramine, when administered to pregnant rats at doses as high as 10 mg/kg, had no overt effect on dam gestational weight gain or number of pups born compared to vehicle injected controls (Montero et al., [@B69]; Goldberg and Nissim, [@B31]). Desipramine at the doses used in this study (all less than 7.5 mg/kg) will have pharmacokinetic effects (see Table [1](#T1){ref-type="table"} for details) of near total inhibition of the NE transporter and mild to minimal inhibition of the 5-HT transporter (Gould et al., [@B33]). In addition to their effects as monoamine reuptake inhibitors, both amitriptyline and desipramine function as neuronal sodium and potassium channel blockers when administered in the μM concentration range (Nicholson et al., [@B72]). Cerebral spinal fluid concentrations of amitriptyline and desipramine achieved in this experiment fall in the nM concentration range (see Table [1](#T1){ref-type="table"}), making blockade of sodium or potassium channels in central nervous system unlikely. At the site of subcutaneous injection, both amitriptyline and desipramine would have been present for short periods of time at μM concentrations. Thus, amitriptyline and desipramine may have functioned as local anesthetics for a period of hours post-injection. All local anesthetic effects would have dissipated by the time of parturition and postpartum behavior testing.

###### 

**Estimated cerebral spinal fluid concentration by drug dose and reported Ki for individual monoamine transporter proteins**.

  Drug            Dose (mg/kg)   Plasma (nM)   Plasma protein binding (%)   CSF (nM)   Ki (nM)          
  --------------- -------------- ------------- ---------------------------- ---------- --------- ------ -------
  Amitriptyline   8              82            95                           4.1        84        13.9   8600
                  15             371           95                           18.55      84        13.9   8600
  Desipramine     7.5            664           90                           66.4       180       0.6    11000

*Table reviewing available literature of studies using: chronic subcutaneous administration, adult rats, drugs of interest at comparable doses to those used in this study, and reported plasma concentrations \[8 mg/kg amitriptyline (Brodin et al., [@B11]), 15 mg/kg amitriptyline (Benmansour et al., [@B5]), and 7.5 mg/kg desipramine (Gould et al., [@B33])\]. Reported cerebrospinal fluid (CSF) concentrations were calculated by multiplying reported drug plasma concentrations and reported plasma protein binding percentages \[amitriptyline (Schulz et al., [@B88]) and desipramine (Sallee and Pollock, [@B82])\]. Reported Ki values for serotonin (5-HT), norepinephrine (NE), and dopamine (DA) transport proteins are for rat synaptosomes (Bolden-Watson and Richelson, [@B7])*.

Treatment
---------

The females were randomly assigned to one of seven treatment groups, or as an untreated surrogate. Throughout gestation (GD 1--20), treatment groups received twice daily subcutaneous (SC) injections (on alternating flanks) of either drug (amitriptyline or desipramine) or 0.9% normal saline for controls in a 1-ml/kg volume at 9:00 AM, with all control and treatment dams receiving normal saline at 4:00 PM (2 ml/kg total) to match previous treatment regimens used to test MB and MA (Johns et al., [@B41]). Amitriptyline treated rats received either a low, medium, or high dose SC injection (2.5, 5, or 10 mg/kg respectively) of amitriptyline hydrochloride (Research Biomedicals Inc., Natick, MA, USA) in a pH 10 solution (0.1 ml 1 N NaOH and 0.6 ml of 0.1 N HCl in distilled water) at 9:00 AM. on one flank, followed by their saline injection at 4:00 PM. Desipramine treated rats received either a low, medium, or high dose (1.25, 2.5, or 5.0 mg/kg respectively) of desipramine hydrochloride at 9:00 AM and saline at 4:00 PM. Single rather than twice daily doses of amitriptyline and desipramine were also given because of the long half-life (Ghose, [@B30]) of these drugs and to match previous studies (Johns et al., [@B41]). Twice daily injections given on alternate flanks have been shown to minimize skin trauma from injections, although we saw no significant evidence of skin trauma with amitriptyline as we have seen in previous studies using either cocaine or fluoxetine treatment (Johns et al., [@B41]).

Weight gain was recorded daily except for surrogate dams. Surrogate dams received no treatment other than handling and were weighed every 5 days. All treatment dams received eight age matched male pups from a surrogate dam within 12 h of parturition. All procedures were conducted under an approved protocol using federal and University Institutional Animal Care and Use Committee guidelines for humane treatment of laboratory subjects.

Maternal behavior testing
-------------------------

Upon delivery of their last pup, designated as PPD 1, the dams were brought in their home cage to a 10 × 12 ft. observation room. Dam and pups were not brought to the test room until all pups had delivered, been cleaned and all had milk bands showing they had nursed. This treatment regimen has been used in a number of past studies (Johns et al., [@B48]; Lonstein and Gammie, [@B61]) since a primary interest of this work is in the onset of MB when oxytocin is most relevant. Dams and their litters were brought to the test chamber for habituation only after they have cleaned all pups and pups have milk bands. Since dams had time to clean and feed their pups before they were separated, an essential element for maternal response, we do not feel pup separation on PPD 1 disrupted MB. Pilot work showed when pups are removed immediately after birth and mothers are not given time to clean or feed pups overall MB is reduced but this is not the case with this paradigm. The home cage was placed into a 24 × 16 × 20 in. dimly lit testing cubicle, designed to reduce environmental distractions during testing, and the subject's pups were removed. Gestational weight gain and length, litter size and weight, and gender of pups were recorded. Eight male surrogate pups born within 12 h of a test dam's delivery were placed in a warm cage above the test cubicles while the dam to be tested habituated to the room for 30 min. After the habituation period, 10 pieces of nesting material (paper towel strips) were placed at the rear of the cage and the eight male surrogate pups were placed in the front of the cage. Surrogate pups were used to control for any confounds of pup behavioral differences related to prenatal drug exposure that might affect maternal care. Cross fostering at this time point has been shown in a number of previous studies in our laboratory to have no deleterious effects on maternal acceptance of offspring, given that all mothers have nursed and cleaned their own litters and pups are readily accepted and cared for (Johns et al., [@B41]). Untreated male surrogate pups were used to eliminate the possible effects of differential pup treatment due to gender preference, which has sometimes been reported (Hahn and Lavooy, [@B35]), we have seen little evidence of this in past testing with other drug treatment paradigms (Johns et al., [@B41]). MB was tested on PPD 1 both to compare to previous studies and because we were most interested in the early onset of MB, which is most dependent on oxytocin system related changes. Videotaping with a VHS recorder with low light sensitivity began as soon as the pups were placed into the cage and continued for 30 min. All pups were observed for any physical danger from the dam during testing. Typical MBs of interest in our lab, which have been previously described (Johns et al., [@B48]), focus primarily on activity and pup-directed behavior displayed by the dam. These include: nest-build (dam manipulates paper strips with her mouth or paws); touch/sniff pups (dam touches pups with her front paws or nose); retrieve pups (dam retrieves two, six or eight pups from the front to the back of the cage); self-groom (dam grooms herself with her tongue or paws); rest off/lie on (dam rests away from the pups or lies flat on top of pups); crouch (dam stands over the pups with her back arched in the nursing position with stiff straight legs and head lowered); lick pups (dam licks the pups); rear/sniff (dam rears and sniffs the cage or air); and other (any behavior other than those designated above including locomotor activity). Following MB testing, dams and their surrogate litters were returned to the colony and monitored daily to assure pup health. This model used to study rodent maternal neglect has been employed successfully in previous studies following gestational drug treatment (Henderson and McMillen, [@B37]).

Postpartum aggression testing
-----------------------------

On PPD 6, dams and their litters were brought in their home cage to the behavioral observation room where pups and dams were weighed. PPD 6 was chosen for the study of MA testing to match previous studies which show that drug related changes have peak effects on MA on this day (Johns et al., [@B41]). Additionally, oxytocin system changes in the amygdala are particularly associated with behavioral increases in aggressive behavior by PPD 6. Dams and litters were then returned to their home cages which were then placed in the testing cubicle for a 5 min chamber habituation period. Following the habituation period, a smaller male intruder (175 g) was placed in the cage on the end opposite the dam and her litter, and the session was videotaped for a 10-min period. The sessions were closely observed for danger to the pups, male intruder, or dam, and if harm appeared imminent then the session was stopped and data from that session was excluded from the statistical analysis. A new male was used for each test so that previous experience of the intruder would not affect their behavior. Following testing, the male was removed from the cage, and the dam and pups were returned to the colony room. The behaviors of interest for postpartum aggression have been previously described (Lubin et al., [@B62]), and include: push/box/kick (dam pushes or kicks the intruder); MB (dam licks pups, retrieves, or crouches over pups); rough groom (dam grooms intruder male roughly, usually around head, neck, or back); self-groom (dam grooms herself); lateral/front threat (dam threatens male while approaching laterally, or face to face); fight attack (a quick lunge by the female usually followed by rolling, biting, and fur pulling directed toward the neck and back regions of the intruder); rear/sniff (dam rears on hind legs and sniffs the top or sides of cage); nip/bite (dam nips or bites male but not in a fight attack); chase male (female chases intruder); aggressive posture (dam stands over a submissive intruder with extended front paws pressing down on him); and other (any behavior other than those included in the categories above).

Brain dissection
----------------

On PPD 7, at approximately 9:00 AM, 1 day following postpartum aggression testing, dams were killed by decapitation. The brain was removed and the whole MPOA, hippocampus, amygdala, and VTA were dissected on ice, weighed, and rapidly frozen and stored at −80°C for later oxytocin radioimmunoassay as previously described (Johns et al., [@B44]). Brains were coronally sectioned from the ventral side rostral to the optic chiasm, approximately A7100 (Konig and Klippel, [@B56]), and just caudal to the optic chiasm, approximately A5800 (Konig and Klippel, [@B56]), to define the preoptic--anterior hypothalamic area. The MPOA was dissected by making a horizontal cut ventral to the anterior commissure and vertical cuts inferior to the lines of lateral ventricles. The brains were sectioned once again just caudal to the tuber cinereum, approximately A3800 (Konig and Klippel, [@B56]), to define the medial basal hypothalamus. The amygdala was removed from these two sections. The VTA was dissected from the caudal section by making dorso-ventral cuts medial to the optic tracts with a dorsal cut at the ventral extent of the central gray and the whole hippocampus was then removed from the caudal remainder of the brain.

Oxytocin radioimmunoassay
-------------------------

Brain region tissues were homogenized in cold buffer (19 mM monobasic sodium phosphate, 81 mM dibasic sodium phosphate, 0.05 M NaCl, 0.1% BSA, 0.1% Triton 100, 0.1% sodium azide, pH 7.4) and centrifuged at 3000 × *g* for 30 min. Oxytocin immunoreactive content was assayed in the supernatant according to a protocol from Peninsula Labs (Belmont, CA, USA). Samples and standards (1.0--128.0 pg) were incubated in duplicate for 16--24 h at 4°C with rabbit anti-oxytocin serum. They were then incubated for 16--24 h at 4°C with ^125^I-oxytocin after which time normal rabbit serum and goat anti-rabbit IgG serum were added and incubated 90 min at room temperature. The ^125^I-oxytocin bound to the antibody complex was separated from free by a 30-min centrifugation at 4°C. The radioactivity in the pellet was measured using a LKB CliniGamma counter, which calculates the picogram content of oxytocin in each sample from the standard curve.

Data analyses
-------------

Taped sessions were scored by two independent observers blind to treatment condition with inter-and intra-reliability set at 90% or better concurrence for frequency and latency, and 80% or better for duration of behaviors displayed by the dam. No sessions had to be excluded for physical danger to the pups during testing for MB or MA. A computer program calculated the frequency, duration, latency, and sequence of all relevant behaviors displayed by the rat dams. If a particular behavior of interest was not exhibited by a dam, she was assigned a frequency and duration of 0, and the highest possible latency for the behavior (1800 s for MB, and 600 s for MA). Weighted additive models for time to event best fit the duration data analyzed from the MB dataset as well as the oxytocin and gestational datasets. Log linear models for count data fit the frequency data analyzed from the postpartum aggression dataset best. These models were used to examine within drug group differences (high, medium, low dose) as well as between drug group differences (amitriptyline, desipramine, saline) in all datasets.

Considering the large number of observations made for MB and postpartum aggression for each dam, general estimating methods were used to obtain group estimates and standard errors. Additionally *p*-values were adjusted for multiple comparisons via the FDR method (Benjamini et al., [@B4]). Only measures we felt most relevant to our specific hypotheses were chosen *a priori*, for group comparison for both MB (duration of touch, crouch, lick) and a composite measure of activity (combined categories of other and rear/sniff) and for postpartum aggression (frequency of threat, fight attack, and aggressive posture). Using the Pearson product-moment correlation coefficient, there were no significant direct correlations between oxytocin levels on PPD 7 and aggression measures on PPD 6, thus comparisons of oxytocin levels (picograms/mg) were made between all groups for all four brain regions. Estimates of the means and standard errors under the model are presented graphically for frequency and duration data. Statistical significance was set at the *p* ≤ 0.05 level. Results are significant unless otherwise stated and are presented in the text under relevant subheadings and reported first within each drug (amitriptyline-A, desipramine-D), at each treatment level (high-H, medium-M, low-L), between drug treatment and control treatment (saline) dam groups, and lastly between corresponding drug treatment groups (for example, amitriptyline high dose treatment vs. desipramine high dose treatment). Statistically significant results directly relevant to hypotheses are described in text, with details of all statistical comparisons and individual significance levels contained in relevant figures and legends. Groups are designated by abbreviations of their respective drug or control (amitriptyline/desipramine/saline) groups, followed by letters (see above) indicating dose level. For example, desipramine low dose treatment dams would be labeled as DL.

Results {#s1}
=======

Gestation variables
-------------------

Dam test numbers are noted in Table [2](#T2){ref-type="table"} with the exception of a lower number of MB dams coded in the AH (7 total) and DM (9 total) dam groups compared to those coded for postpartum aggression testing, brain oxytocin level measurement, and gestational variables. This was the result of VHS tape failure during recording or playback of MB testing sessions for these animals. Though no MB data was available for those particular dams, they all completed MB testing so their data were included for remaining assessments of postpartum aggression, brain oxytocin levels, and gestational variables.

###### 

**Gestational variables**.

  Drug     Number tested (\# dams)   Gestational length (days)   Dam weight gain (g)   Litter weight on PPD 1 (g)   Average birth litter size (\# pups)   Average PPD 1 pup weight (g/pup)   Surrogate litter weight PPD 1 (g)   Surrogate litter weight gain PPD 1--6 (g)
  -------- ------------------------- --------------------------- --------------------- ---------------------------- ------------------------------------- ---------------------------------- ----------------------------------- -------------------------------------------
  AH       11 \*                     21.0 ± 0.14                 132.27 ± 5.51         78.82 ± 4.50 *l*             12.55 ± 0.80                          6.31 ± 0.14                        47.64 ± 2.08 *M,S,d*                41.45 ± 2.94 *M,L,S,d*
  AM       7                         21.0 ± 0.18                 146.57 ± 6.92         81.43 ± 5.64                 12.86 ± 1.00                          6.32 ± 0.18                        59.71 ± 2.60 *l*                    60.43 ± 3.69
  AL       9                         21.0 ± 0.16                 137.33 ± 6.10         93.67 ± 4.97                 14.78 ± 0.88                          6.37 ± 0.15                        50.33 ± 2.30 *s*                    53.67 ± 3.25
  Saline   9                         21.0 ± 0.15                 147.11 ± 6.10         89.67 ± 4.97                 14.11 ± 0.88                          6.42 ± 0.15                        58.11 ± 2.30                        60.78 ± 3.25
  DH       11                        20.91 ± 0.14                142.45 ± 5.52         81.73 ± 4.50                 14.00 ± 0.80                          5.85 ± 0.14 *S,a*                  57.18 ± 2.08                        52.45 ± 2.94 *a*
  DM       11 \*                     20.64 ± 0.14                130.27 ± 5.52 *s*     75.27 ± 4.50 *s*             13.09 ± 0.80                          5.78 ± 0.14 *S,a*                  56.73 ± 2.08                        52.45 ± 2.94
  DL       11                        21.00 ± 0.14                140.00 ± 5.52         83.00 ± 4.50                 13.91 ± 0.88                          6.08 ± 0.14                        53.45 ± 2.08                        51.45 ± 2.94 *s*

Mean ± SEM of all gestational measures. Group means designated with an *italicized lower case* letters are statistically significant at *p* ≤ 0.05, *italicized CAPITAL* letters are significant at the *p* ≤ 0.01. *h, m*, and *l* denotes a significant difference between high, medium, and low dose groups within a drug treatment group. An *s* denotes significant differences between drug treatment group and saline control; *a* denotes statistical difference for a desipramine group from corresponding amitriptyline treatment group; and a *d* for a amitriptyline group from corresponding desipramine treatment group. By corresponding treatment group authors mean that high, medium, and low doses in the amitriptyline groups were compared to the same relative doses (i.e., high, medium, low) in the desipramine groups. AH, amitriptyline high group (10 mg/kg); AM, amitriptyline medium (5 mg/kg); AL, amitriptyline low (2.5 mg/kg); DH, desipramine high (5 mg/kg); DM, desipramine medium (5 mg/kg); DL, desipramine low (1.25 mg/kg); Saline (2 ml/kg). \*The number of coded observations of MB was reduced in the DH and DM groups as stated in the Section ["Results."](#s1){ref-type="sec"}

### Amitriptyline

There were no significant differences within or between amitriptyline treatment and saline control groups on the measures of gestation length, gestational weight gain, or birth litter size (see Table [2](#T2){ref-type="table"}). AL dams' weight on gestational day 0 was significantly higher than both AM dams \[χ^2^~(1)~ = 6.85, *p* ≤ 0.01\] and saline control dams \[χ^2^~(1)~ = 4.24, *p* ≤ 0.05\]. AH birth litters weighed less on PPD 1 than AL \[χ^2^~(1)~ = 4.91, *p* ≤ 0.05\], however average individual AH pup weight did not differ (litter weight divided by litter number) at this time, suggesting this is an effect of slight differences in litter number (not significantly different) rather than individual pup size. On PPD 1, AH surrogate litters weighed less than surrogate litters of AM \[χ^2^~(1)~ = 13.15, *p* ≤ 0.01\] and saline control litters \[χ^2^~(1)~ = 11.45, *p* ≤ 0.01\]. Surrogate litters of AH dams gained significantly less over PPDs 1--6 than did those of AM \[χ^2^~(1)~ = 16.16, *p* ≤ 0.01\], AL \[χ^2^~(1)~ = 7.75, *p* ≤ 0.01\] or saline control litters \[χ^2^~(1)~ = 19.40, *p* ≤ 0.01\].

### Desipramine

There were no significant differences within any desipramine treated or between desipramine and saline dams on gestation length, birth litter size, or PPD 1 surrogate litter weight. DM dams gained less weight across gestation (GD 1--20) than did saline dams \[χ^2^~(1)~ = 4.19, *p* ≤ 0.05, see Table [2](#T2){ref-type="table"}\]. DL dams' weight on GD 0 was significantly higher than both DH \[χ^2^~(1)~ = 4.75, *p* ≤ 0.05\] and saline control \[χ^2^~(1)~ = 8.78, *p* ≤ 0.01\] dams. The average individual pup weight of DH litters on PPD 1 was lower than saline controls \[χ^2^~(1)~ = 7.66, *p* ≤ 0.01\]. DM litters had a lower litter birth weight \[χ^2^~(1)~ = 4.61, *p* ≤ 0.05\] and individual pup birth weight \[χ^2^~(1)~ = 9.42, *p* ≤ 0.01\] than did litters born to saline dams.

### Amitriptyline vs. desipramine

As illustrated in Table [2](#T2){ref-type="table"}, AH surrogate litters gained less weight over PPDs 1--6, than did DH litters \[χ^2^~(1)~ = 6.98, *p* ≤ 0.01\]. AM dams weighed less on GD 0 than DM dams \[χ^2^~(1)~ = 5.17, *p* ≤ 0.05\]. AH and AM birth litters had higher average individual pup weights on PPD 1 than DH \[χ^2^~(1)~ = 5.62, *p* ≤ 0.05\] and DM \[χ^2^~(1)~ = 5.75, *p* ≤ 0.05\] litters, respectively.

Maternal behavior
-----------------

### Amitriptyline

There were significant within treatment dose effects with amitriptyline groups and between amitriptyline and saline control groups on all measures of MB analyzed (see Figure [1](#F1){ref-type="fig"}). AH dams crouched for a shorter duration than all other amitriptyline dams AM \[χ^2^~(1)~ = 17.69, *p* ≤ 0.01\]; AL \[χ^2^~(1)~ = 15.26, *p* ≤ 0.01\] or saline controls \[χ^2^~(1)~ = 20.81, *p* ≤ 0.01\]. Interestingly, the AH dams touched pups more AM \[χ^2^~(1)~ = 13.77, *p* ≤ 0.01\]; AL \[χ^2^~(1)~ = 12.89, *p* ≤ 0.01\]; saline controls \[χ^2^~(1)~ = 8.13, *p* ≤ 0.01\] and also licked them longer than other dams AM \[χ^2^~(1)~ = 17.14, *p* ≤ 0.01\]; AL \[χ^2^~(1)~ = 18.91, *p* ≤ 0.01\]; saline controls \[χ^2^~(1)~ = 18.88, *p* ≤ 0.01\]. Finally, AH dams were generally more active than other dams AM \[χ^2^~(1)~ = 19.65, *p* ≤ 0.01\]; AL \[χ^2^~(1)~ = 11.45, *p* ≤ 0.01\]; and saline controls \[χ^2^~(1)~ = 24.63, *p* ≤ 0.01\], as shown in Figure [1](#F1){ref-type="fig"}.

![**Mean ± SEM of all MB measures organized in four panels of bar charts for all amitriptyline groups**. Each panel is for a specific behavior \[**(A)** Crouch; **(B)** Activity; **(C)** Lick; **(D)** Touch\]. All four panels measure duration in seconds (s) on the *Y* axis and *X* axis includes categories for all amitriptyline groups and saline controls. Gray bars denote amytriptyline groups \[AH, amitriptyline high (10 mg/kg); AM, amitriptyline medium (5 mg/kg); AL, amitriptyline low (2.5 mg/kg)\]. While bars denote saline control group \[Saline = normal saline (2 ml/kg)\]. \* *p* ≤ 0.05; \*\**p* ≤ 0.01.](fpsyt-02-00034-g001){#F1}

### Desipramine

DH \[χ^2^~(1)~ = 3.94, *p* ≤ 0.05\] and DM \[χ^2^~(1)~ = 6.05, *p* ≤ 0.05\] dams crouched less than did saline treated dams, as shown in Figure [2](#F2){ref-type="fig"}. The DM dams were more active \[χ^2^~(1)~ = 4.60, *p* ≤ 0.05\] than were the saline controls. There were no other statistically significant between group differences on MB measures in desipramine or saline control dams.

![**Mean ± SEM of all MB measures organized in four panels of bar charts for all desipramine groups**. Each panel is for a specific behavior \[**(A)** Crouch; **(B)** Activity; **(C)** Lick; **(D)** Touch\]. All four panels measure duration in seconds (s) on the *Y* axis and *X* axis includes categories for all desipramine groups and saline controls. Black bars denote desipramine groups \[DH, desipramine high (5 mg/kg); DM, desipramine medium (2.5 mg/kg); DL, desipramine low (1.25 mg/kg)\]. While bars denote saline control group \[Saline = normal saline (2 ml/kg)\]. \* *p* ≤ 0.05; \*\**p* ≤ 0.01.](fpsyt-02-00034-g002){#F2}

### Amitriptyline vs. desipramine

AH dams crouched over pups for a shorter duration \[χ^2^~(1)~ = 8.47, *p* ≤ 0.01\] but touched \[χ^2^~(1)~ = 7.77, *p* ≤ 0.01\] and licked \[χ^2^~(1)~ = 19.53, *p* ≤ 0.01\] pups longer than did the DH dams (see Figure [3](#F3){ref-type="fig"}). AH dams were also more active \[χ^2^~(1)~ = 19.95, *p* ≤ 0.01\] than were DH dams in general. Conversely, AM dams crouched longer than did DM \[χ^2^~(1)~ = 4.84, *p* ≤ 0.05\] dams while DM and DL dams touched pups longer than did AM \[χ^2^~(1)~ = 5.31, *p* ≤ 0.05\] or AL \[χ^2^~(1)~ = 5.49, *p* ≤ 0.05\] dams.

![**Mean ± SEM of all MB measures organized in four panels of bar charts by behavior for all amitriptyline and desipramine groups**. Each panel is for a specific behavior \[**(A)** Crouch; **(B)** Activity; **(C)** Lick; **(D)** Touch\]. All four panels measure duration in seconds (s) on the *Y* axis and *X* axis includes categories for all amitriptyline groups in gray \[AH, amitriptyline high group (10 mg/kg); AM, amitriptyline medium (5 mg/kg); AL, amitriptyline low (2.5 mg/kg)\], all desipramine groups in black \[DH, desipramine high (5 mg/kg); DM, desipramine medium (5 mg/kg); DL, desipramine low (1.25 mg/kg)\] and saline control group in white \[Saline = normal saline (2 ml/kg)\]. Comparisons between amitriptyline and desipramine groups were only tested between the high, medium, or low dose groups for each respective drug treatment group. All significant AH--DH, AM--DM, and AL--DL comparisons are denoted \**p* ≤ 0.05; \*\**p* ≤ 0.01.](fpsyt-02-00034-g003){#F3}

Postpartum aggression
---------------------

### Amitriptyline

As shown in Figure [4](#F4){ref-type="fig"}, AH dams attacked intruders less saline controls \[χ^2^~(1)~ = 5.26, *p* ≤ 0.05\], had a higher frequency of aggressive postures aggressive posture AL only \[χ^2^~(1)~ = 5.63, *p* ≤ 0.05\] and threatened intruders less than other dam groups all dams, AM \[χ^2^~(1)~ = 14.84, *p* ≤ 0.01\]; AL \[χ^2^~(1)~ = 50.16, *p* ≤ 0.01\]; and saline controls \[χ^2^~(1)~ = 16.03, *p* ≤ 0.01\]. AL dams threaten intruders more than AM \[χ^2^~(1)~ = 6.29, *p* ≤ 0.05\] or saline treated dams \[χ^2^~(1)~ = 9.48, *p* ≤ 0.05\].

![**Mean ± SEM of all postpartum aggression measures organized in three panels of bar charts by behavior between **(A)** all amitriptyline and saline, **(B)** all desipramine and saline, and **(C)** all amitryptline and desipramine groups**. All panels measure frequency of behavior on the *Y* axis and *X* axis includes categories for all amitriptyline groups in gray \[AH, amitriptyline high group (10 mg/kg); AM, amitriptyline medium (5 mg/kg); AL, amitriptyline low (2.5 mg/kg)\], all desipramine groups in black \[DH, desipramine high (5 mg/kg); DM, desipramine medium (5 mg/kg); DL, desipramine low (1.25 mg/kg)\]) and saline control group in white \[Saline = normal saline (2 ml/kg)\]. Comparisons between amitriptyline and desipramine groups were only tested between the high, medium, or low dose groups for each respective drug treatment group. All significant AH--DH, AM--DM, and AL--DL comparisons are denoted \**p* ≤ 0.05; \*\**p* ≤ 0.01.](fpsyt-02-00034-g004){#F4}

### Desipramine

As shown in Figure [4](#F4){ref-type="fig"}, all desipramine dams threatened intruders less than saline treated dams DH \[χ^2^~(1)~ = 40.36, *p* ≤ 0.01\]; DM \[χ^2^~(1)~ = 31.52, *p* ≤ 0.01\]; and DL \[χ^2^~(1)~ = 24.71, *p* ≤ 0.01\]. DH treated dams also attacked intruders less DM \[χ^2^~(1)~ = 11.18, *p* ≤ 0.01\]; saline controls \[χ^2^~(1)~ = 16.47, *p* ≤ 0.01\], and were less likely to pin intruders with an aggressive posture than were other dam groups DM \[χ^2^~(1)~ = 4.13, *p* ≤ 0.05\]; DL \[χ^2^~(1)~ = 6.09, *p* ≤ 0.05\]; saline controls \[χ^2^~(1)~ = 7.46, *p* ≤ 0.01\]. DL dams attacked intruders less often than did saline treated dams \[χ^2^~(1)~ = 6.33, *p* ≤ 0.05\].

### Amitriptyline vs. desipramine

All doses of amitriptyline significantly increased the frequency of threat when compared to their corresponding high \[χ^2^~(1)~ = 5.56, *p* ≤ 0.05\], medium \[χ^2^~(1)~ = 28.36, *p* ≤ 0.01\], or low \[χ^2^~(1)~ = 65.85, *p* ≤ 0.01\] dose desipramine groups (see Figure [4](#F4){ref-type="fig"}). AH dams had a higher frequency of aggressive postures compared to DH dams \[χ^2^~(1)~ = 17.58, *p* ≤ 0.01\].

Oxytocin radioimmunoassay
-------------------------

### Amitriptyline

AL dams had higher oxytocin levels in the MPOA than did saline controls \[χ^2^~(1)~ = 3.99, *p* ≤ 0.05\]. AH \[χ^2^~(1)~ = 30.20, *p* ≤ 0.01\], AM \[χ^2^~(1)~ = 40.15, *p* ≤ 0.01\], and AL \[χ^2^~(1)~ = 46.83, *p* ≤ 0.01\] treated dams all had lower hippocampal levels of oxytocin (pg/mg) compared to saline controls (see Figure [5](#F5){ref-type="fig"}).

![**Mean ± SEM of all brain oxytocin measures organized in four panels of bar charts by anatomical region for all amitriptyline and desipramine groups**. Each panel is for a specific anatomical region \[**(A)** MPOA; **(B)** Hippocampus; **(C)** VTA; **(D)** Amygdala). All four panels measure picograms of oxytocin per milligram of brain tissue (pg/mg) on the *Y* axis and *X* axis includes categories for all amitriptyline groups in gray \[AH, amitriptyline high group (10 mg/kg); AM, amitriptyline medium (5 mg/kg); AL, amitriptyline low (2.5 mg/kg)\], all desipramine groups in black \[DH, desipramine high (5 mg/kg); DM, desipramine medium (5 mg/kg); DL, desipramine low (1.25 mg/kg)\] and saline control group in white \[Saline = normal saline (2 ml/kg)\]. Comparisons between amitriptyline and desipramine groups were only tested between the high, medium, or low dose groups for each respective drug treatment group. All significant AH--DH, AM--DM, and AL--DL comparisons are denoted \**p* ≤ 0.05; \*\**p* ≤ 0.01.](fpsyt-02-00034-g005){#F5}

### Desipramine

As seen in Figure [5](#F5){ref-type="fig"}, there were no significant differences between desipramine and saline control groups on levels of oxytocin in the MPOA, amygdala, or the VTA. DH treated dams had significantly lower levels of oxytocin (pg/mg) in the hippocampus compared to saline controls \[χ^2^~(1)~ = 31.43, *p* ≤ 0.01\] and significantly increased hippocampal oxytocin levels compared to DM dams \[χ^2^~(1)~ = 7.06, *p* ≤ 0.01\]. DM \[χ^2^~(1)~ = 66.05, *p* ≤ 0.01\] and DL dams \[χ^2^~(1)~ = 50.47, *p* ≤ 0.01\] also had lower hippocampal oxytocin levels than did saline treated dams.

### Amitriptyline vs. desipramine

There were no significant differences between amitriptyline and desipramine groups on oxytocin levels in any brain region tested.

Discussion
==========

We predicted that gestational desipramine treatment would have less effect on MB compared to amitriptyline treatment based on previous work with serotonergic reuptake inhibitors (Johns et al., [@B41]). Our present data supports this hypothesis as combined 5-HT/NE reuptake inhibition resulted in greater MB alterations compared to NE reuptake inhibition alone. Chronic NE reuptake inhibition by the medium and high doses of desipramine in this study resulted in decreased crouching of dams compared to saline treated controls, and desipramine treatment was generally associated with lower levels of aggression. Results from this study support previous findings indicating a role for NE in MB. Previous studies have suggested NE plays a role in pup retrieval and disrupted nursing, as Thomas and Palmiter ([@B95]) reported that pups born to mice lacking NE did not exhibit visible milk bands. However, the data ultimately indicated the deficits in pup feeding resulted primarily from poor maternal retrieval, resulting in a high percentage of pup litters not surviving (Thomas and Palmiter, [@B95]). In the present study, all dams retrieved pups with no differences in the latency to retrieve (data not shown), suggesting disruptions in crouching behavior in the desipramine treated dams were not related to retrieval. Although DM dams were more active than controls, the DH dams were not, so for this group at least hyperactivity did not prevent crouching. Crouching, or assuming the nursing posture, by dams is one of the most important dam behaviors in the early postpartum period for pup survival, as they need to nurse often and starting soon after birth. Since untreated, surrogate pups were fostered to dams, we assume that pup behavior such as kneading and moving to stay under the ventrum was adequate to stimulate dams to assume the posture, and that variability in pup response would be random. NE may affect milk production by dams, and although we did not check specifically for amount of milk in dams, it is possible they could have produced somewhat less milk and thus spent less time crouching. As only the DL litters gained less weight from PPD 1--6 (see Table [2](#T2){ref-type="table"}) than controls and DL dams did not differ in crouching, this argues against this interpretation. Given the evidence, we might surmise that the desipramine treatment either directly or indirectly altered this crouching behavior.

Previous studies have suggested NE may play a role in aggressive behavior of male mice, with effects dependent on the treatment and drug regimen (Matsumoto et al., [@B64]). Higher levels of NE have been previously associated with increased aggression in adult male human prisoners (Chichinadze et al., [@B14]), but few effects have been reported with respect to females in rodent or human models. In the present study, desipramine treatment decreased all aggressive behaviors measured. This is interesting as we expected no increases but did not predict significant decreases. Chronic reuptake inhibition, which would have resulted in lower levels of NE during the course of treatment, might have resulted in decreased NE levels or noradrenergic receptor binding at the time of MA testing (Bondi et al., [@B8]), or, alternatively, the withdrawal from desipramine may have resulted in a rebound by PPD 6 testing. Our findings support previous data suggesting NE can alter MA under some regimens, with an emphasis now on lactating females. Since we did not measure levels of NE or receptors on PPD 6, we can only speculate as to which mechanisms might be responsible for the observed behavioral effects.

While manipulations of 5-HT levels have been correlated with MB changes, few investigators have studied this association directly. Findings presented here suggest that combined NE and 5-HT reuptake inhibition has a greater impact on crouching compared to gestational treatment with drugs which affect either NE or 5-HT systems individually (Johns et al., [@B41]). In addition, it appears more likely that activity changes may have played a role in amitriptyline related effects. Reduced crouching behavior is more of a passive behavior whereas increased touching and licking of pups seen in the high dose amitriptyline dams is more appetitive and activity specific. In light of our previous findings (Johns et al., [@B41]) that chronic 5-HT reuptake inhibition (fluoxetine) alone results in strong trends for decreased crouching and increased levels of licking and touching of pups, we feel that amitriptyline's effects are very similar to fluoxetine, and somewhat different from NE reuptake inhibition alone (crouching deficits only). It seems through manipulation of the independent and combined monoamine neurotransmitter systems in this and other studies (Johns et al., [@B41]), that particular behaviors may be more strongly related to specific effects of one particular monoamine neurotransmitter rather than the combination of effects from several systems. However, it is important to note that behavioral changes observed here with the highest dose of amitriptyline, could also be related to altered DA reuptake. Although amitriptyline is relatively selective for NE and 5-HT, Di Matteo et al. ([@B22]) reported an increase in DA levels in the nucleus accumbens following acute amitriptyline administration at the highest dose (10 mg/kg) used here. Gestational treatment with a low dose of a DA reuptake inhibitor also has been shown to reduce crouching, decrease latency to lick and increase pup licking and touching (Johns et al., [@B41]). Future studies could examine the impact of drug dose on specific neurotransmitter system dynamics (levels, binding) to aid in interpreting pharmacological findings.

Higher 5-HT levels have been correlated with lower levels of aggression in numerous reports in rodent models, especially male rodents (Olivier and Mos, [@B74]; Olivier et al., [@B75]; Holmes et al., [@B38]; Miczek et al., [@B68]). Few reports are available for female models, particularly lactating females employing single reuptake inhibitors over gestation. Previously, we reported that dams treated chronically with fluoxetine during gestation at a high dose (8 mg/kg) resulted in dams that were less likely to nip/bite or threaten an intruder, but more likely to attack and fight them for a longer duration than controls (Johns et al., [@B41]). This is interesting in light of our present findings (contrary to our predictions) that AH treated dams actually threatened and attacked intruders less than other amitriptyline treated and control dams. Overall, all amitriptyline treated dams threatened intruders more often compared to all desipramine treated dams, suggesting that lower levels of NE may play an inhibitory role in MA. In humans, amitriptyline has generally been found to increase aggression (Soloff et al., [@B90], [@B91]), suggesting again that the combined reuptake of 5-HT and NE might interact to offset the effect of 5-HT inhibition alone. Doses of amitriptyline and desipramine were selected to ensure minimal DA reuptake inhibition and retained selectivity for 5-HT and NE transporters; these findings are somewhat similar to the effects of combined DA and 5-HT reuptake inhibition during gestation in that the additive effect of a DA reuptake inhibitor dampens the heightened aggression following fluoxetine (Johns et al., [@B41]). The doses used here do, however, have different pharmacokinetic effects on the monoamine transporters. Future studies where doses of amitriptyline and desipramine are selected to achieve different percent inhibition of 5-HT and NE transporters may produce more pronounced behavioral and neuroendocrine effects, and aid in a clearer understanding of specific neurotransmitter involvement in MBs.

We predicted oxytocin levels would be decreased in the amygdala if they were associated with increased MA following amitriptyline treatment. In light of low levels of aggression observed in both treatment groups, it is not surprising that we did not observe any oxytocin increases in the amygdala. It is plausible that the aggression levels, specifically fighting, must be significantly higher to find the related oxytocin changes we have previously seen following treatment with drugs that alter multiple reuptake inhibitor systems (Johns et al., [@B48], [@B24]) or following gestational treatment with some doses of a DA reuptake inhibitor (Johns et al., [@B42]). It may also be the case as we and others have suggested, and this study may indicate, that specific types of aggression may be differentially associated with oxytocin level changes in different brain regions (Caldwell et al., [@B12]; Bosch et al., [@B9]; Consiglio et al., [@B18]; McMurray et al., [@B67]; Johns et al., [@B45]). Oxytocin levels were significantly lower in the hippocampus following treatment with either drug compared to saline controls, just as was the case in our earlier report using selective serotonergic and dopaminergic reuptake inhibitors (Johns et al., [@B41]). The hippocampus has been more strongly associated with MB (Kimble et al., [@B55]) than with MA specifically in lactating models. Reduced levels (Johns et al., [@B44]) and receptors (Jarrett et al., [@B39]) for oxytocin in the early postpartum environment have been reported following treatment with cocaine, a non-selective monoaminergic reuptake inhibitor. The hippocampus is well known for its role in integration spatiotemporal memories (Hasselmo et al., [@B36]) and the hippocampus exhibits increased BOLD signal in response to pup suckling which can be reduced by OT antagonists (Febo et al., [@B25]). The entorhinal cortex, directly adjacent to the hippocampus, is involved in social memory and also exhibits the positive BOLD response to pup suckling (Febo et al., [@B25]). These results suggest a role for hippocampal OT sensory response to pups, perhaps encoding spatial memories of where the sensory stimulation occurred, although this has yet to be tested. Oxytocin has previously been shown to modulate neuroplasticity in the hippocampus, inducing long-term potentiation in the hippocampus of postpartum mice (Tomizawa et al., [@B96]) and long-term depression in male rats (Dubrovsky et al., [@B23]). Hippocampal oxytocin has been associated with drug dependence and tolerance (Sarnyai and Kovacs, [@B83]), and as such may be playing a role in the present findings. Pervasive decreases in hippocampal oxytocin with gestational administration of a wide variety of monoaminergic agents, coupled with oxytocin's known role as a modulator of hippocampal synaptic strength and potential role in social recognition and perception (Cole and Young, [@B17]; Theodoridou et al., [@B94]), warrant future studies assessing the role of monoaminergic reuptake inhibitors on hippocampal neuroplasticity in the maternal brain.

The present study was not without limitations, including no direct assessment of changes in NE, 5-HT, and DA levels or receptors in brain regions of interest following drug treatment. Our focus on the oxytocin system prevented these measurements of monoamine system function in a single cohort of animals. The use of only male surrogate pups results in a loss of generalizability of the effects to a larger population, although previous studies have shown drug-induced effects with mixed litters as well (Johns et al., [@B40]). The drugs chosen for this study were not the most selective available for the respective neurotransmitter systems, but in some respects quite relevant considering treatment for serotonin selective reuptake inhibitor refractory depression employs the use of combined NE/5-HT neurotransmitter uptake inhibitors like amitriptyline and desipramine. However, as observed here, particular dose pharmacokinetics need to be further explored, as low and medium doses of amitriptyline had little effect on MB, and drug dose-behavior relationship studies aimed at understanding complex mechanisms driving behavioral changes could be of clinical relevance.

While we did not assess changes in anxiety and stress in this particular study, both have been correlated with deficits in maternal care (Smith et al., [@B89]; Bosch et al., [@B10]; Chen et al., [@B13]; Kessler et al., [@B52]). To the extent that dams in this study may have been experiencing some effects of drug withdrawal at time of testing (none were noted), it is important to acknowledge that this could have had some effects on the behaviors measured here. We did not detect any problems with lesions or distress following either drug administration. While the AH dams did gain less gestational weight they did not suffer notable sudden weight loss. Milk production did not seem to be restricted in AH dams as all pups nursed and had milk bands. These animals were more active and perhaps there were some anorectic effects as were evident in a previous fluoxetine study at the high dose level (Johns et al., [@B41]) which could have had some effects on behaviors measured. It is also important to remember that effects of drugs used as antidepressants in an animal model must be carefully interpreted, as this model does not have an overt depressive-like phenotype (Pollak et al., [@B77]), and as such, may not reflect the pharmacological effects these compounds would have in depressed or drug abusing human mothers. Future studies like this one using an animal model of depression might prove interesting. In conclusion, given the high rates women use legal and illicit monoamine reuptake inhibitors, further exploration of these models could prove useful for studying how the action of these drugs may alter the dynamics of the mother--infant relationship. This study, in combination with other previous reports, highlights the complexity and importance of understanding the biological underpinnings of maternal care.
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